独バイオ企業Evotecは21日、慢性腎臓疾患治療薬の開発で製薬大手の英AstraZenecaと提携すると発表した。Evotecがスクリーニング技術で特定した化合物をAstraZenecaが利用して新薬を開発する。Evotecは契約一時金のほか、一定目標を達成するごとに報酬を受ける。また市販化に成功した場合は売り上げの一定比率を受け取る。取引金額は非公開。
\
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |